Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Up 3.9% – Here’s Why

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) shares traded up 3.9% during trading on Tuesday . The company traded as high as $25.53 and last traded at $25.53. 39,443 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 232,475 shares. The stock had previously closed at $24.57.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, December 29th. Evercore assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 target price for the company. UBS Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They set a “buy” rating and a $45.00 price objective for the company. Guggenheim reiterated a “buy” rating and set a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Finally, Lifesci Capital upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Damora Therapeutics, Inc. Common Stock currently has a consensus rating of “Moderate Buy” and an average target price of $44.25.

Damora Therapeutics, Inc. Common Stock Price Performance

The stock has a 50 day simple moving average of $26.79 and a 200-day simple moving average of $20.82. The firm has a market cap of $1.49 billion, a PE ratio of -2.04 and a beta of 1.59.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $40,000. Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $266,000. Virtu Financial LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth $49,000. Sigma Planning Corp bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $334,000. Finally, Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth $76,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.